Caraten Drug Interactions

Metabolism/Transport Effects Substrate of CYP1A2 (minor), CYP2C9 (major), CYP2D6 (major), CYP2E (minor), CYP3A4 (minor), P-glycoprotein; lnhibits P-glycoprotein: Avoid Concomitant Use: Avoid concomitant use of Carvedilol with any of the following: Dabigatran Etexilate; Methacholine; Topotecan.
lncreased Effect/Toxicity: Carvedilol may increase the levels/effects of: Alpha-/Beta- Agonist(Direct-Acting); Alpha1-Blockers; Alpha2-Agonists; Amifostine; Antihypertensive; Antipsychotic Agents(phenothiazine); Cardiac Glycosides; Colchicine; Cyclosporin; Dabigatran Etexilate; Digoxin; hypotensive agents; Insulin; Lidocaine systemic and topical; Methacholine; Midodrine; P-Glycoprotein Substrates; Rituximab; Rivaroxaban; Sulfonylureas; Topotecan.
The levels/effects of Carvedilol may be increased by Acetylcholinesterase inhibitors; Aminoquinolines(antimalarial); Amiodarone; Anilidopiperidine Opioids; Phenothiazines; Non-dihydropyridine calcium channel blockers; Cimetidine; CYP2C9 inhibitors (moderate/ strong); CYP2D6 inhibitors (moderate /strong); Darunavir; Diazoxide; Dipyridamole; Disopyramide; Dronedarone; Herbs (Hypotensive properties); MAO Inhibitors; Pentoxifylline; P-Glycoprotein Inhibitors; Phosphodiesterase 5 Inhibitors; Propafenone; Propoxyphene; Prostacyclin Analogues; Quinidine; Reserpine; Selective Serotonin Reuptake Inhibitors.
Decreased Effect: Carvedilol may decrease the level/effects of: Beta2 Agonists; Theophylline Derivatives.
The levels/effects of Carvedilol may be decreased by Barbiturates; Herbs(hypertensive properties); Methylphenidate; NSAIDs; Peginterferon Alfa-2b; P-Glycoprotein inducers; Rifampicin Derivatives; Yohimbine.